Missouri is currently home to 1892 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Saint Louis, Kansas City, St. Louis and Springfield. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
ZIP Study-OL Study of Safety, PK, Efficacy, PD, Immunogenicity of ATB200/AT2221 in Pediatrics Aged 0 to < 18 y.o. w/LOPD
NCT03911505
Recruiting
This is a Phase 3, open-label, multicenter study to evaluate the safety, PK, efficacy, PD, and immunogenicity of Cipaglucosidase Alfa/Miglustat treatment in enzyme replacement therapy (ERT)-experienced and ERT-naïve pediatric subjects with Pompe disease, aged 0 to \< 18 years
Gender:
ALL
Ages:
Between 0 years and 17 years
Trial Updated:
09/16/2024
Locations: St. Louis Children's Hospital, Saint Louis, Missouri
Conditions: Pompe Disease (Late-onset)
Register for Updates
Carboplatin or Olaparib for BRcA Deficient Prostate Cancer
NCT04038502
Recruiting
This is an unblinded, randomized clinical study comparing the efficacy of DNA damaging chemotherapy using carboplatin, to standard of care therapy for patients who have metastatic castrate resistant prostate cancer. This trial will use olaparib or carboplatin as initial therapy with crossover to the alternate or second-line drug after first progression for patients with tumors containing BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2, RAD51B, RAD51C, RAD51D, or RAD54L inactivating mutations. P... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
09/13/2024
Locations: Kansas City VA Medical Center, Kansas City, MO, Kansas City, Missouri
Conditions: Metastatic Castrate Resistant Prostate Cancer, BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2, RAD51B, RAD51C, RAD51D, or RAD54L Mutations
Register for Updates
Post Approval Study - Evaluate the Long-Term Safety and Effectiveness of the WEB Device
NCT04839705
Recruiting
A prospective, multicenter, single arm, interventional study. The target patient population for this study are adult subjects with WNBAs of the anterior and posterior intracranial circulation. The primary effectiveness outcome of the study is adequate intracranial aneurysm occlusion on the 1 year angiogram as adjudicated by a core laboratory.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/12/2024
Locations: The Washington University, Saint Louis, Missouri
Conditions: Wide Neck Bifurcation Intracranial Aneurysms
Register for Updates
NEXUS Aortic Arch Clinical Study to Evaluate Safety and Effectiveness
NCT04471909
Recruiting
Prospective, non-randomized, multi-center clinical investigation of the NEXUS™ Aortic Arch Stent Graft System (NEXUSTM) for the treatment of thoracic aortic lesions involving the aortic arch with a proximal landing zone, native or previously implanted surgical graft, in the ascending aorta and with a brachiocephalic trunk native landing zone.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/11/2024
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Aortic Dissection, Aortic Aneurysm, Intramural Hematoma, Penetrating Aortic Ulcer
Register for Updates
A Phase 2 Open Label Study of BA3021 in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
NCT05271604
Recruiting
This is a multi-center, open-label Phase 2 study designed to evaluate the efficacy and safety of BA3021 as monotherapy and combination therapy in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/10/2024
Locations: Washington University Medical Siteman Cancer Center, Saint Louis, Missouri
Conditions: Head and Neck Cancer, Squamous Cell Carcinoma of Head and Neck, Recurrent Squamous Cell Carcinoma of the Head and Neck, Metastatic Cancer, Metastatic Squamous Cell Carcinoma of the Head and Neck
Register for Updates
Online Peri-operative Education Program for Patients Undergoing Major Head & Neck Surgery
NCT05954676
Recruiting
This phase of the project will evaluate the utility and efficacy of a personalized online patient education platform developed from efforts in Phase 1 in 1) increasing patients' and caregivers' pre- and post-operative preparedness and satisfaction, and 2) reducing readmission, ED/Urgent care/unplanned clinic visits and telephone calls to clinic staff.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/09/2024
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Head and Neck Cancer, Head and Neck Neoplasms
Register for Updates
RNA Disruption Assay (RDA)-Breast Cancer Response Evaluation for Individualized Therapy
NCT03524430
Recruiting
The current study aims to provide validation results of RNA Disruption Assay (RDA) as a tumour response assessment tool that uses tumour core biopsies taken starting from 35 +/- 4 days after the initiation of neoadjuvant chemotherapy.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
09/09/2024
Locations: Siteman Cancer Center, Saint Louis, Missouri
Conditions: Breast Neoplasm Female
Register for Updates
Baker Gordon Syndrome Natural History Study
NCT06399952
Recruiting
The goal of this study is to conduct a prospective, longitudinal assessment of the natural clinical progression of children and adults with Synaptotagmin1-Associated Neurodevelopmental Disorder also known as Baker Gordon Syndrome (BAGOS). This will be performed by acquiring baseline measurements and developing effective outcome measures and diagnostic tools for the disorder, to prepare the healthcare system for future clinical trials.
Gender:
ALL
Ages:
Between 0 years and 99 years
Trial Updated:
09/06/2024
Locations: University of Missouri Columbia, Columbia, Missouri
Conditions: Rare Diseases, Autism or Autistic Traits, Development Delay, SYT-SSX Fusion Protein Expression, Sleep Disorder, Epilepsy, Generalized, Motor Delay
Register for Updates
Compassionate Use of Domperidone for Refractory Gastroparesis
NCT04699591
Recruiting
The purpose of this program is to allow the use of domperidone in children from 12 to 21 years of age with symptoms related to motility disorders and Gastroesophageal reflux disease (GERD) who have failed all the standard treatments for their condition.
Gender:
ALL
Ages:
Between 12 years and 21 years
Trial Updated:
09/05/2024
Locations: Children's Mercy Hospitals and Clinics, Kansas City, Missouri
Conditions: GERD, Gastroesophageal Reflux, Gastroparesis
Register for Updates
Sex-specific Effect of Restricted Sleep on Brain Health
NCT05920759
Recruiting
The goal of this clinical trial is to compare the impact of restricted sleep on brain blood health in healthy men and women. The main question\[s\] it aims to answer are: * Whether morning cerebral blood flow velocity is greater following a night of normal sleep compared to restricted sleep * Whether the effect of sleep restriction on cerebral blood flow will be greater in males compared to females Participants will complete one 1-hour screening visit and two 2.5-hour study visits. Study visits... Read More
Gender:
ALL
Ages:
Between 18 years and 45 years
Trial Updated:
09/03/2024
Locations: University of Missouri, Columbia, Missouri
Conditions: Cerebrovascular Circulation
Register for Updates
Membrane Target Detection for Leukemia Treatment
NCT04841447
Recruiting
Acute myeloid leukemia (AML) accounts for more than 40% of leukemia mortality in the United States. Each year around ten thousand people die from the disease, most within a few years of diagnosis. Despite advances in our understanding of the disease, few improvements in the therapy of AML have been made. Collecting specimens from the blood and bone marrow will increase understanding of the effect of Dipeptidyl Peptidase-4 (DPP-4) Inhibitors on human AML-SCP to develop individualized therapies. W... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/03/2024
Locations: University of Missouri, Columbia, Missouri
Conditions: Hematological Malignancy
Register for Updates
Pre-emptive Therapy With DEC-C to Improve Outcomes in MDS Patients With Measurable Residual Disease Post Allogeneic Hematopoietic Cell Transplant
NCT04742634
Recruiting
The investigators hypothesize that early measurable residual disease (MRD)-guided pre-emptive therapy with decitabine + cedazaridine (DEC-C) will decrease the risk of progression in post-transplant myelodysplastic syndromes (MDS) patients with persistent mutations (molecular MRD). To detect molecular MRD, the investigators will perform ultra-deep, error-corrected panel-based sequencing (MyeloSeq-HD) at Day 30 in post-transplant MDS patients. The investigators will treat patients with detectable... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
09/02/2024
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Myelodysplastic Syndromes
Register for Updates